News

Explore Latest News .

Find all the latest news on Paul Peter Tak, as well as a comprehensive list of his past interviews and features. Paul Peter’s work in immunology and the pharmaceutical industry has led him to be featured in both business and medicine specific publications.

During his time at GlaxoSmithKline, Paul Peter gave a number of interviews and briefs, including one with the Biochemical Society in 2017. In this insightful interview, Paul Peter outlined what the GSK Immunology Network was and its impact on this important area of research.

In December 2020, Paul Peter Tak spoke with Eleanor Malone, from Scrip, about the work Candel Therapeutics was undertaking in the field of cancer immunotherapy and the companies ambitious future. Paul Peter has also had more broad discussions around his career and what inspires him, such as his interview with Stephanie Sutton for The Medicine Maker, in 2020.

Paul Peter Tak named to PharmaVoice’s 100 List

Pharma Voice’s 100 list is a prestigious compilation that recognizes influential leaders and innovators in the pharmaceutical and life sciences industry. Among the distinguished individuals acknowle…

We’re excited to join the @Nasdaq family! Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL

Candel Therapeutics appoints Diem Nguyen, Ph.D., M.B.A., to Board of Directors

https://www.businesswire.com/news/home/20210715005303/en/Candel-Therapeutics-Appoints-Diem-Nguyen-Ph.D.-M.B.A.-to-Its-Board-of-Directors

Exciting times at Candel Therapeutics

Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here’s what you need to know about the 5 new biotechs filing for IPOs

The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile.

https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Onc…

Candel Therapeutics at the Jefferies Virtual Healthcare Conference 2021

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Exec…

Contact Me

Paul Peter Tak

contact@paulpetertak.com